2,467 results match your criteria Current Opinion in Lipidology[Journal]


Integrative roles of microRNAs in lipid metabolism and dyslipidemia.

Curr Opin Lipidol 2019 Apr 9. Epub 2019 Apr 9.

Department of Molecular Physiology and Biophysics, Vanderbilt University.

Purpose Of Review: The purpose of the review is to discuss recent advances in microRNA (miRNA) regulation of lipid metabolism and highlight the importance of miRNA-mediated gene regulation in dyslipidemia and fatty liver disease. This article reviews examples of miRNAs that bridge disparate metabolic pathways in the liver. For example, we highlight miRNAs that are regulated by the sterol-sensing pathway in the liver that in turn regulate cellular or systemic cholesterol, fatty acid, and glucose levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000603DOI Listing

Genetics-driven discovery of novel regulators of lipid metabolism.

Curr Opin Lipidol 2019 Apr 9. Epub 2019 Apr 9.

Cardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University, New York, New York, USA.

Purpose Of Review: Residual cardiovascular disease risk and increasing metabolic syndrome risk underscores a need for novel therapeutics targeting lipid metabolism in humans. Unbiased human genetic screens have proven powerful in identifying novel genomic loci, and this review discusses recent developments in such discovery.

Recent Findings: Recent human genome-wide association studies have been completed in incredibly large, detailed cohorts, allowing for the identification of more than 300 genomic loci that participate in the regulation of plasma lipid metabolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000605DOI Listing
April 2019
2 Reads

Regulation of lipid rafts, angiogenesis and inflammation by AIBP.

Curr Opin Lipidol 2019 Apr 9. Epub 2019 Apr 9.

Department of Medicine, University of California, San Diego, La Jolla, California, USA.

Purpose Of Review: Recent studies demonstrate an important role of the secreted apolipoprotein A-I binding protein (AIBP) in regulation of cholesterol efflux and lipid rafts. The article discusses these findings in the context of angiogenesis and inflammation.

Recent Findings: Lipid rafts are cholesterol-rich and sphingomyelin-rich membrane domains in which many receptor complexes assemble upon activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000596DOI Listing
April 2019
1 Read

Role of sortilin in lipid metabolism.

Authors:
Donna M Conlon

Curr Opin Lipidol 2019 Apr 2. Epub 2019 Apr 2.

Division of Translational Medicine and Human Genetics, Department of Medicine, University of Pennsylvania, Philadelphia, USA.

Purpose Of Review: Sortilin, encoded SORT1 gene at chromosome 1p13.3, is a multiligand receptor that traffics protein from the Golgi to the endosomes, secretory vesicles, and the cell surface. Genome-wide association studies (GWAS) revealed an association between sortilin and reduced plasma LDL-cholesterol (LDL-C) as well as reduced coronary artery disease (CAD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000598DOI Listing
April 2019
2 Reads

HDL from an Alzheimer's disease perspective.

Curr Opin Lipidol 2019 Apr 2. Epub 2019 Apr 2.

Department of Pathology and Laboratory Medicine.

Purpose Of Review: We review current knowledge regarding HDL and Alzheimer's disease, focusing on HDL's vasoprotective functions and potential as a biomarker and therapeutic target for the vascular contributions of Alzheimer's disease.

Recent Findings: Many epidemiological studies have observed that circulating HDL levels associate with decreased Alzheimer's disease risk. However, it is now understood that the functions of HDL may be more informative than levels of HDL cholesterol (HDL-C). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000604DOI Listing
April 2019
2 Reads

Proprotein convertase subtilisin/kexin type 9 and lipid metabolism.

Curr Opin Lipidol 2019 Mar 28. Epub 2019 Mar 28.

Department of Medicine, Columbia University, New York, New York, USA.

Purpose Of Review: The purpose of this review is to highlight the recent findings of one of the most promising therapeutic targets in LDL cholesterol (LDL-C) management, proprotein convertase subtilisin/kexin type 9 (PCSK9).

Recent Findings: Endoplasmic reticulum cargo receptor, surfeit locus protein 4 interacts with PCSK9 and regulates its exit from endoplasmic reticulum and its secretion. Once secreted, PCSK9 binds to heparin sulfate proteoglycans on the hepatocyte surface and this binding is required for PCSK9-LDL receptor (LDLR) complex formation and LDLR degradation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000601DOI Listing

Senescent cells in the development of cardiometabolic disease.

Curr Opin Lipidol 2019 Mar 22. Epub 2019 Mar 22.

Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Purpose Of Review: Senescent cells have recently been identified as key players in the development of metabolic dysfunction. In this review, we will highlight recent developments in this field and discuss the concept of targeting these cells to prevent or treat cardiometabolic diseases.

Recent Findings: Evidence is accumulating that cellular senescence contributes to adipose tissue dysfunction, presumably through induction of low-grade inflammation and inhibition of adipogenic differentiation leading to insulin resistance and dyslipidaemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000602DOI Listing
March 2019
2 Reads

The E3 ubiquitin ligase inducible degrader of the LDL receptor/myosin light chain interacting protein in health and disease.

Curr Opin Lipidol 2019 Mar 20. Epub 2019 Mar 20.

Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.

Purpose Of Review: The RING E3 ubiquitin ligase inducible degrader of the LDL receptor (IDOL, also known as MYLIP) promotes ubiquitylation and subsequent lysosomal degradation of the LDL receptor (LDLR), thus acting to limit uptake of lipoprotein-derived cholesterol into cells. Next to the LDLR, IDOL also promotes degradation of two related receptors, the very LDL receptor (VLDLR) and apolipoprotein E receptor 2 (APOER2), which have important signaling functions in the brain. We review here the emerging role of IDOL in lipoprotein and energy metabolism, neurodegenerative diseases, and the potential for therapeutic targeting of IDOL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000593DOI Listing
March 2019
1 Read

New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk.

Authors:
Sander Kersten

Curr Opin Lipidol 2019 Mar 18. Epub 2019 Mar 18.

Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, Wageningen, the Netherlands.

Purpose Of Review: The angiopoietin-like proteins (ANGPTLs), consisting of ANGPTL3, ANGPTL4, and ANGPTL8, have gained significant interest for their role as inhibitors of lipoprotein lipase (LPL) and for their potential as therapeutic targets for correcting dyslipidemia. This review provides an overview of the most relevant new insights on the connection between ANGPTLs, plasma lipids, and coronary artery disease.

Recent Findings: Carriers of loss-of-function variants in ANGPTL3 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and LDL-C, while carriers of loss-of-function variants in ANGPTL4 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and increased HDL-C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000600DOI Listing
March 2019
1 Read

Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application.

Curr Opin Lipidol 2019 Mar 22. Epub 2019 Mar 22.

Department of Pediatrics, Section of Molecular Metabolism and Nutrition, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Purpose Of The Review: Several members of the fibroblast growth factor (FGF) family have been identified as key regulators of energy metabolism in rodents and nonhuman primates. Translational studies show that their metabolic actions are largely conserved in humans, which led to the development of various FGF-based drugs, including FGF21-mimetics LY2405319, PF-05231023, and pegbelfermin, and the FGF19-mimetic NGM282. Recently, a number of clinical trials have been published that examined the safety and efficacy of these novel therapeutic proteins in the treatment of obesity, type 2 diabetes (T2D), nonalcoholic steatohepatitis (NASH), and cholestatic liver disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000599DOI Listing

CRISPR: a promising tool for lipid physiology and therapeutics.

Curr Opin Lipidol 2019 Mar 22. Epub 2019 Mar 22.

Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, Texas, USA.

Purpose Of Review: The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Recent Findings: The CRISPR/Cas9 system has been used to generate knockout animals for lipid genes in multiple species. Somatic genome editing with CRISPR/Cas9 can efficiently disrupt genes in adult animals, including a new strategy for generating atherosclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000591DOI Listing

Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?

Curr Opin Lipidol 2019 Mar 18. Epub 2019 Mar 18.

University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.

Purpose Of Review: The purpose of this review is to discuss the influence of obesity, insulin resistance, type 2 diabetes (T2D), and nonalcoholic fatty liver disease (NAFLD) on bile acid metabolism and to analyze whether these findings reinforce current beliefs about the role of bile acids in the pathophysiology of these diseases.

Recent Findings: Discordant results on plasma bile acid alterations in NAFLD patients have been reported. Obesity, insulin resistance, and T2D, common comorbidities of NAFLD, have been associated with bile acid changes, but the individual bile acid species variations differ between studies (summarized in this review), perhaps because of clinicobiological differences between the studied patient populations and the heterogeneity of statistical analyses applied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000597DOI Listing
March 2019
1 Read

Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys.

Curr Opin Lipidol 2019 Apr;30(2):154-155

Saha Cardiovascular Research Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000583DOI Listing
April 2019
1 Read

Endoscopic bariatric treatments: new toolkit in the armamentarium against obesity.

Curr Opin Lipidol 2019 Apr;30(2):151-153

Oak Ridge Gastroenterology Associates, Oak Ridge, Tennessee, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000585DOI Listing

Genomics of familial hypercholesterolaemia.

Curr Opin Lipidol 2019 Apr;30(2):148-150

Unidade de I&D, Grupo de Investigação Cardiovascular, Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000584DOI Listing
April 2019
2 Reads

Editorial introduction.

Authors:

Curr Opin Lipidol 2019 Apr;30(2)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000588DOI Listing

The biochemical and genetic diagnosis of lipid disorders.

Curr Opin Lipidol 2019 Apr;30(2):56-62

Eurofins Genomics, Louisville, Kentucky, USA.

Purpose Of Review: To examine recent advances in our knowledge on the diagnosis of lipid disorders.

Recent Findings: Fasting values above the 99th percentile for direct LDL-cholesterol (LDL-C), lipoprotein(a), and triglycerides are greater than 225 mg/dl, greater than 160 mg/dl, and greater than 500 mg/dl (>5.82, >394, and >5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000590DOI Listing
April 2019
2 Reads

Recently reported familial hypercholesterolemia-related mutations from cases in the Middle East and North Africa region.

Curr Opin Lipidol 2019 Apr;30(2):88-93

Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University.

Purpose Of Review: Familial hypercholesterolemia is an inherited disorder where cases have a significantly higher risk of having premature myocardial infarction than noncases. The prevalence of this genetic disease is currently unknown in countries of the Middle East and North Africa region. Given that a high percentage of marriages are consanguineous in this region, the prevalence may be much higher than assumed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000586DOI Listing
April 2019
1 Read

The evolution of genetic-based risk scores for lipids and cardiovascular disease.

Curr Opin Lipidol 2019 Apr;30(2):71-81

Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University.

Purpose Of Review: With improved next-generation sequencing technology, open-access genetic databases and increased awareness of complex trait genetics, we are entering a new era of risk assessment in which genetic-based risk scores (GRSs) will play a clinical role. We review the concepts underlying polygenic models of disease susceptibility and challenges in clinical implementation.

Recent Findings: Polygenic risk scores are currently used in genetic research on dyslipidemias and cardiovascular disease (CVD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000576DOI Listing
April 2019
1 Read

From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants.

Curr Opin Lipidol 2019 Apr;30(2):101-107

Montreal Heart Institute, Atherosclerosis Research Group.

Purpose Of Review: The validity of HDL-cholesterol (HDL-C) elevation as a therapeutic target has been questioned, in comparison to enhancing HDL functionality. Cholesterol efflux capacity (CEC) is an in-vitro assay that measures the ability of an individual's HDL to promote cholesterol efflux from cholesterol donor cells such as macrophages. CEC of HDL is a predictor of cardiovascular risk independent of HDL-C levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000589DOI Listing
April 2019
20 Reads

Editorial: designing targeted sequencing panels for dyslipidemia.

Authors:
Robert A Hegele

Curr Opin Lipidol 2019 Apr;30(2):53-55

Departments of Medicine and Biochemistry, Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000579DOI Listing
April 2019
1 Read

Progress in finding pathogenic DNA copy number variations in dyslipidemia.

Curr Opin Lipidol 2019 Apr;30(2):63-70

Robarts Research Institute, and Department of Biochemistry, Schulich School of Medicine and Dentistry.

Purpose Of Review: DNA copy number variations (CNVs) are large-scale mutations that include deletions and duplications larger than 50 bp in size. In the era when single-nucleotide variations were the major focus of genetic technology and research, CNVs were largely overlooked. However, CNVs clearly underlie a substantial proportion of clinical disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000581DOI Listing
April 2019
2 Reads

Pathways of smooth muscle foam cell formation in atherosclerosis.

Curr Opin Lipidol 2019 Apr;30(2):117-124

Department of Medicine, Centre for Heart Lung Innovation, Providence Healthcare Research Institute at St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.

Purpose Of Review: Smooth muscle cells (SMCs) are the major cell type in human atherosclerosis-prone arteries and take up excess lipids, thereby contributing to luminal occlusion. Here we provide a focused review on pathways by which smooth muscle cells (SMCs) can become foam cells in atherosclerosis.

Recent Findings: A synthesis of recent and older investigations provides key mechanistic insights into SMC foam cell formation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000574DOI Listing
April 2019
1 Read

Unaccounted risk of cardiovascular disease: the role of the microbiome in lipid metabolism.

Curr Opin Lipidol 2019 Apr;30(2):125-133

Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.

Purpose Of Review: Not all of the risk of cardiovascular disease can be explained by diet and genetics, and the human microbiome, which lies at the interface of these two factors, may help explain some of the unaccounted risk. This review examines some of the well established links between the microbiome and cardiovascular health, and proposes relatively unexplored associations.

Recent Findings: Byproducts of microbial metabolism are associated with health and disease: Trimethylamine N oxide is associated with atherosclerosis; whereas short-chain fatty acids are associated with decreased inflammation and increased energy expenditure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000582DOI Listing
April 2019
3 Reads

Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.

Curr Opin Lipidol 2019 Apr;30(2):82-87

Heart Institute (InCor) University of Sao Paulo Medical School Hospital.

Purpose Of Review: To discuss the heterogeneity of atherosclerotic cardiovascular disease (ASCVD) risk in heterozygous familial hypercholesterolemia and evidence and limitations of clinical risk scores and subclinical coronary atherosclerosis (SCA) imaging to evaluate risk.

Recent Findings: Risk evaluation in contemporary familial hypercholesterolemia cohorts needs to consider the cause of the familial hypercholesterolemia phenotype, for example the presence of autosomal molecular defects that impart a greater ASCVD risk than in polygenic hypercholesterolemia, prospective follow-up and the impact of statin treatment. As atherosclerosis is multifactorial, clinical scores like the Montreal familial hypercholesterolemia score and SAFEHEART risk equation have been proposed to stratify ASCVD in statin-treated, molecularly defined familial hypercholesterolemia individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000573DOI Listing
April 2019
13 Reads

Current status of familial hypercholesterolemia in Chinese populations.

Curr Opin Lipidol 2019 Apr;30(2):94-100

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.

Purpose Of Review: Heterozygous familial hypercholesterolemia often went unrecognized in China when population cholesterol levels were low, but rapid economic development has changed the situation. This review will discuss the current position of awareness, diagnosis, and management of familial hypercholesterolemia in Chinese populations.

Recent Findings: The phenotype of familial hypercholesterolemia in China and other Chinese populations has become similar to that in Western countries, although it may still be somewhat less severe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000580DOI Listing
April 2019
9 Reads

Cannabis effects on lipoproteins.

Curr Opin Lipidol 2019 Apr;30(2):140-146

Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University.

Purpose Of Review: The endocannabinoid system affects several physiological functions. A family of endocannabinoid receptors is susceptible to cannabis constituents. Cannabis is widely used in our society and following its recent legalization in Canada, we focus on how exposure to cannabis and pharmacologic cannabinoid receptor type 1 (CB1) inhibition affect lipoprotein levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000575DOI Listing
April 2019
1 Read

Molecular regulation of plasma lipid levels during systemic inflammation and sepsis.

Curr Opin Lipidol 2019 Apr;30(2):108-116

Centre for Heart Lung Innovation.

Purpose Of Review: Sepsis is a common syndrome of multiorgan system dysfunction caused by a dysregulated inflammatory response to an infection and is associated with high rates of mortality. Plasma lipid and lipoprotein levels and composition change profoundly during sepsis and have emerged as both biomarkers and potential therapeutic targets for this condition. The purpose of this article is to review recent progress in the understanding of the molecular regulation of lipid metabolism during sepsis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000577DOI Listing
April 2019
8 Reads

Chylomicron retention disease: genetics, biochemistry, and clinical spectrum.

Curr Opin Lipidol 2019 Apr;30(2):134-139

Research Centre.

Purpose Of Review: Chylomicron retention disease (CRD) is an autosomic recessive disorder, in which intestinal fat malabsorption is the main cause of diverse severe manifestations. The specific molecular defect was identified in 2003 and consists of mutations in the SAR1B or SARA2 gene encoding for intracellular SAR1B GTPase protein. The aim of this review is first to provide an update of the recent biochemical, genetic and clinical findings, and second to discuss novel mechanisms related to hallmark symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000578DOI Listing
April 2019
3 Reads

Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.

Curr Opin Lipidol 2019 Feb;30(1):1-9

Department of Biochemistry.

Purpose Of Review: Bempedoic acid has emerged as a potent inhibitor of ATP-citrate lyase (ACLY), a target for the reduction of LDL cholesterol (LDL-C). We review the impact of bempedoic acid treatment on lipoprotein metabolism and atherosclerosis in preclinical models and patients with hypercholesterolemia.

Recent Findings: The liver-specific activation of bempedoic acid inhibits ACLY, a key enzyme linking glucose catabolism to lipogenesis by catalyzing the formation of acetyl-CoA from mitochondrial-derived citrate for de novo synthesis of fatty acids and cholesterol. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00041433-201902000-0000
Publisher Site
http://dx.doi.org/10.1097/MOL.0000000000000565DOI Listing
February 2019
25 Reads

Atherosclerosis: cell biology and lipoproteins.

Curr Opin Lipidol 2019 Feb;30(1):50-52

Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000562DOI Listing
February 2019
1 Read

An evolutionary look at cholesterol.

Authors:
Uwe J F Tietge

Curr Opin Lipidol 2019 Feb;30(1):48-49

Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000563DOI Listing
February 2019
2 Reads

Breastfeeding and cardiovascular risk factors.

Curr Opin Lipidol 2019 Feb;30(1):45-47

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000564DOI Listing
February 2019
9 Reads

Lipoprotein metabolism in liver diseases.

Curr Opin Lipidol 2019 Feb;30(1):30-36

Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Purpose Of Review: The liver is the central hub of lipoprotein metabolism. A complex relationship exists between dyslipidemia and chronic liver diseases (CLDs). Recent advances in the genetics of nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) exemplify the pivotal role of lipoprotein metabolism in the pathogenesis of CLD. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00041433-900000000-9939
Publisher Site
http://dx.doi.org/10.1097/MOL.0000000000000569DOI Listing
February 2019
9 Reads

Effects of apolipoprotein E on nutritional metabolism in dementia.

Curr Opin Lipidol 2019 Feb;30(1):10-15

Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Healthcare System.

Purpose Of Review: Various groups have explored the effect of apolipoprotein E (APOE) on neurodegeneration through nutritional and metabolic alterations. In this review, we hope to summarize recent findings in humans as well as preclinical APOE models.

Recent Findings: Metabolic pathways including lipid metabolism appear to play a large role in the pathophysiology of Alzheimer's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000566DOI Listing
February 2019
2 Reads

HDL modification: recent developments and their relevance to atherosclerotic cardiovascular disease.

Curr Opin Lipidol 2019 Feb;30(1):24-29

Departments of Chemistry and Molecular Biosciences and the Proteomics Center of Excellence.

Purpose Of Review: In the last 2 years, significant advances in the understanding of HDL particle structure and the associations between particle structure, function, and atherosclerosis have been made. We will review and provide clinical and epidemiological context to these recent advances.

Recent Findings: Several recent studies have analyzed the associations between HDL particle size distribution, number, and particle function and specific environmental, behavioral, and pharmacologic exposures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000571DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439474PMC
February 2019
2 Reads

Effects of exercise on HDL functionality.

Curr Opin Lipidol 2019 Feb;30(1):16-23

Department of Exercise Science, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.

Purpose Of Review: Low HDL-cholesterol (HDL-C) levels are a strong predictor of cardiovascular disease risk and can be improved with regular exercise. However, raising HDL-C levels pharmacologically has not shown convincing clinical benefits. Thus, research has recently focused on identifying therapies that improve HDL function, with exercise representing such a potential therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000568DOI Listing
February 2019
2 Reads

Dietary fat and risk of type 2 diabetes.

Curr Opin Lipidol 2019 Feb;30(1):37-43

Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf.

Purpose Of Review: Nutrition recommendations emphasize that not only dietary fat quantity but also fat quality plays a role in the prevention of type 2 diabetes (T2D). The aim of this review is to summarize the evidence for dietary fat and risk of T2D, to highlight recent findings and point out future research directions.

Recent Findings: Total fat intake was not associated with risk of T2D, whereas the findings on fatty acids (FAs) and risk of T2D were controversial. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00041433-900000000-9939
Publisher Site
http://dx.doi.org/10.1097/MOL.0000000000000567DOI Listing
February 2019
96 Reads

Emerging roles of HDL in immune function.

Curr Opin Lipidol 2018 Dec;29(6):486-487

Department of Medicine and Pediatrics, Cardiovascular Research Institute, University of California Medical Center, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000555DOI Listing
December 2018
2 Reads

Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?

Curr Opin Lipidol 2018 Dec;29(6):445-452

Fundación Hipercolesterolemia Familiar, Madrid, Spain.

Purpose Of Review: Familial hypercholesterolemia is a frequent genetic disease associated with lifelong elevation of LDL-cholesterol and premature atherosclerotic cardiovascular disease (ASCVD). Statins are the cornerstone of treatment. However, with the introduction of novel LDL-cholesterol-lowering therapies, it is necessary to identify familial hypercholesterolemia patients presenting a significantly high residual ASCVD risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000553DOI Listing
December 2018
22 Reads

Mendelian randomization causally link lipoproteins to systemic atherosclerosis and help design clinical trials for the future of lipidology.

Curr Opin Lipidol 2018 Dec;29(6):482-483

Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000557DOI Listing
December 2018
1 Read

Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease.

Curr Opin Lipidol 2018 Dec;29(6):433-435

Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000560DOI Listing
December 2018
1 Read

Colchicine: an affordable anti-inflammatory agent for atherosclerosis.

Curr Opin Lipidol 2018 Dec;29(6):467-473

Harry Perkins Institute of Medical Research.

Purpose Of Review: Inflammation has been shown to be central to the development and progression of atherosclerosis. Despite detailed understanding of its central role and the cellular dynamics, which contribute to atherosclerotic inflammation, there has been slow progress in finding suitable agents to treat it. The recent CANTOS trial showed that the interleukin-1β inhibitor canakinumab can improve outcomes after acute coronary syndromes. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00041433-900000000-9940
Publisher Site
http://dx.doi.org/10.1097/MOL.0000000000000552DOI Listing
December 2018
25 Reads

Intestinal cholesterol absorption.

Curr Opin Lipidol 2018 Dec;29(6):484-485

ANZAC Research Institute.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000558DOI Listing
December 2018
2 Reads

The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation.

Curr Opin Lipidol 2018 Dec;29(6):436-444

Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.

Purpose Of Review: We aim to outline the importance and the clinical implications of using predicted individual therapy-benefit in making patient-centered treatment decisions in cardiovascular disease (CVD) prevention. Therapy-benefit concepts will be illustrated with examples of patients undergoing lipid management.

Recent Findings: In both primary and secondary CVD prevention, the degree of variation in individual therapy-benefit is large. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000554DOI Listing
December 2018
4 Reads

RNA-targeted therapeutics for lipid disorders.

Curr Opin Lipidol 2018 Dec;29(6):459-466

Vascular Medicine Program, Sulpizio Cardiovascular Center, Division of Cardiovascular diseases, University of California San Diego School of Medicine, California, USA.

Purpose Of Review: To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

Recent Findings: Despite a number of approved therapies for lipid disorders, significant unmet needs are present in treating persistently elevated LDL-cholesterol, remnant-cholesterol, triglycerides and lipoprotein(a) [Lp(a)]. Small molecules and antibodies are effective modalities, but they are unable to adequately treat many patients with abnormal lipid parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000549DOI Listing
December 2018
2 Reads

Metabolism: The road to inflammation and atherosclerosis.

Curr Opin Lipidol 2018 Dec;29(6):474-480

Department of Experimental Vascular Medicine.

Purpose Of Review: Evidence accumulates suggesting that cellular metabolic alterations fuel and dictate the inflammatory state of cells. In this review, we provide an overview of the observed metabolic reprogramming in endothelial cells and innate immune cells upon interaction with modified lipoproteins, thereby contributing to the progression of atherosclerosis.

Recent Findings: Inflammatory endothelial cells at sites exposed to disturbed flow patterns show increased glycolytic activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000550DOI Listing
December 2018
4 Reads

Key aspects of PCSK9 inhibition beyond LDL lowering.

Curr Opin Lipidol 2018 Dec;29(6):453-458

Purpose Of Review: Our primary objective is to review the most recent findings on the biology of PCSK9 and on two key aspects of PCSK9 inhibition beyond LDL control of great clinical relevance: the regulation of lipoprotein (a) circulating levels by PCSK9 inhibitors and the putative diabetogenic effects of these novel therapies.

Recent Findings: The reality of two distinct extracellular and intracellular pathways by which PCSK9 decreases the abundance of the LDLR at the surface of many cell types, most importantly hepatocytes, has recently been established. In contrast, the exact mechanisms by which PCSK9 inhibitors lower the circulating levels of lipoprotein (a) remain a point of major dispute. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000551DOI Listing
December 2018
2 Reads

Sex differences in metabolism and cardiometabolic disorders.

Curr Opin Lipidol 2018 Oct;29(5):404-410

Department of Medicine/Division of Cardiology.

Purpose Of Review: Sex differences are pervasive in metabolic and cardiovascular traits, yet they have often been ignored in human and animal model research. Sex differences can arise from reversible hormonal effects, from irreversible organizational (developmental) processes, and from gene expression differences from the X and Y chromosomes. We briefly review our current understanding of the impact of these factors in metabolic traits and disorders, with an emphasis on the recent literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOL.0000000000000536DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382080PMC
October 2018
1 Read